AiCuris Anti-Infective Cures

AiCuris Received €15m Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

PREVYMIS now approved in the US and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) EMA approval triggers a €15m Milestone payment to AiCuris and AiCuris is eligible for further milestone payments and royalties on future net sales Obtained funds will further...
Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany

+49 (0)202 317 63 – 0